The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma

Many patients with adenoid-cystic carcinoma (ACC) experience an indolent course of disease over many years but face late recurrence, and long-term survivors are rare. Due to its infrequent occurrence, it is hard to predict outcome in these patients. The fibrinogen-to-lymphocyte ratio (FLR) was recen...

Full description

Saved in:
Bibliographic Details
Published inJournal of personalized medicine Vol. 11; no. 11; p. 1228
Main Authors Brkic, Faris F., Stoiber, Stefan, Friedl, Marlene, Maier, Tobias, Heiduschka, Gregor, Kadletz-Wanke, Lorenz
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 19.11.2021
MDPI
Subjects
Adenoid
adenoid-cystic carcinoma
Cancer therapies
Chemotherapy
Esophagus
Exocrine glands
Fibrinogen
fibrinogen-to-lymphocyte ratio
Gastric cancer
Head and neck carcinoma
Inflammation
Lung cancer
Lymphocytes
Metastasis
Otolaryngology
outcome
Patients
Precision medicine
prognostic marker
Radiation therapy
survival
Tumors
Online AccessGet full text

Cover

More Information
Summary:Many patients with adenoid-cystic carcinoma (ACC) experience an indolent course of disease over many years but face late recurrence, and long-term survivors are rare. Due to its infrequent occurrence, it is hard to predict outcome in these patients. The fibrinogen-to-lymphocyte ratio (FLR) was recently proposed as an outcome prognosticator in different cancer entities. We aimed to investigate its prognostic relevance in patients with head and neck ACC. This retrospective analysis was performed including all patients treated for ACC between 1998 and 2020. The FLR ratio was calculated based on pretreatment values (0–7 days). The study cohort was dichotomized based on optimized threshold value and compared for differences in outcome (overall survival (OS) and disease-free survival (DFS)). In the cohort of 39 included patients, the OS was significantly longer in the low (n = 28) compared to the high pretreatment FLR group (n = 11) (median OS 150.5 months, 95% confidence intervals (CI) 85.3–215.7 months vs. 29.4 months, 95% CI not reached; p = 0.0093). Similarly, the DFS was significantly longer in the low FLR group (median DFS 74.5 months, 95% CI 30.6–118.4 months vs. 11.0 months, 95% CI 5.1–16.9 months; p = 0.019). The FLR is an easily obtainable and simple marker and may be a valuable outcome prognosticator in patients with ACC. Further studies are needed for validation of our results.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm11111228